Inositol

Meta-analyses of RCTs in which pregnant women (often overweight, obese, or with a family history of diabetes) took myo-inositol 2–4 g/day from the first/early second trimester report a lower incidence of gestational diabetes. A 2019 meta of 5 RCTs (n≈965) found roughly halved odds (OR ≈0.49) plus a lower preterm-delivery rate ^{4Reference 4Vitagliano et al. · 2019Meta-analysisInositol for the prevention of gestational diabetes: a systematic review and meta-analysis of randomized controlled trials — meta-analysisView study →}; a 2022 meta reached the same direction ^{5Reference 5Li et al. · 2022Meta-analysisMyo-inositol supplementation for the prevention of gestational diabetes: a meta-analysis of randomized controlled trials — meta-analysisView study →}; and the 2023 Cochrane review of seven studies concluded supplementation “may reduce” gestational diabetes, hypertensive disorders and preterm birth ^{3Reference 3Motuhifonua et al. · 2023Meta-analysisAntenatal dietary supplementation with myo-inositol for preventing gestational diabetes — Cochrane systematic review/meta-analysisView study →}.

All of it is myo-inositol at gram doses started early, not a treatment once diabetes is established.

Gap: most trials are small, single-center (heavily Italian) and not powered for hard neonatal outcomes; Cochrane rates the certainty low and calls for large multi-center confirmation.

In polycystic ovary syndrome, inositol (MI alone, or MI+DCI, typically ~2–4 g MI/day) is used as an insulin-sensitizer to restore ovulatory cycles. A 2023 systematic review of 26 RCTs (1691 women) found the chance of a regular menstrual cycle about 1.8× higher than placebo (RR 1.79, 95% CI 1.13–2.85) and non-inferiority to metformin on most endpoints, with better tolerability ^{2Reference 2Greff et al. · 2023Meta-analysisInositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis — meta-analysisView study →}.

A separate RCT showed MI+DCI (3.6:1) regularized cycles and improved insulin resistance ^{20Reference 20Kachhawa et al. · 2022RCTEfficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome — randomized controlled trialView study →}, and another trial found adding MI to metformin further improved cycle regularity and quality of life versus metformin alone ^{21Reference 21Nazirudeen et al. · 2023RCTA randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome — randomized controlled trialView study →}.

Countering this, the 2024 meta-analysis commissioned for the international PCOS guideline pooled 30 trials and judged the evidence “limited and inconclusive,” benefits confined to some metabolic measures ^{1Reference 1Fitz et al. · 2024Meta-analysisInositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines — meta-analysisView study →}.

Gap: heterogeneous forms, doses and MI:DCI ratios across trials; the highest-rigor guideline synthesis downgrades the reproductive claims, so the honest read is “reasonable, better-tolerated option — not established first-line.”

Beyond PCOS, MI improves insulin signaling markers in insulin-resistant states. In postmenopausal women with metabolic syndrome, MI 2 g twice daily improved HOMA-IR, triglycerides, HDL and blood pressure versus diet alone in a 6-month RCT ^{17Reference 17Giordano et al. · 2011RCTEffects of myo-inositol supplementation in postmenopausal women with metabolic syndrome — randomized controlled trialView study →}, with benefits maintained at one year ^{18Reference 18Santamaria et al. · 2012RCTOne-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome — randomized controlled trialView study →}.

Mechanistically MI (and DCI) act as insulin second-messenger mediators, which is the throughline linking the PCOS, gestational-diabetes and metabolic-syndrome signals.

Gap: trials are modest in size and largely from overlapping Italian groups; effects are on surrogate metabolic markers rather than hard outcomes like incident diabetes.

Two small double-blind crossover RCTs support a genuine anxiolytic effect at high dose. Inositol 12–18 g/day reduced the frequency and severity of panic attacks and agoraphobia more than placebo, with minimal side effects ^{7Reference 7Benjamin et al. · 1995RCTDouble-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder — randomized controlled trialView study →}, and a second crossover trial found inositol not inferior to fluvoxamine over one month ^{8Reference 8Palatnik et al. · 2001RCTDouble-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder — randomized controlled trialView study →}. A 2014 meta-analysis of inositol across anxiety/depression pooled these with other small trials ^{11Reference 11Mukai et al. · 2014Meta-analysisA meta-analysis of inositol for depression and anxiety disorders — meta-analysisView study →}.

Gap: total randomized n is small, crossover designs, all from one research group, and no modern replication — enough for a “cautiously promising” label, not a recommendation.

A 1995 double-blind crossover RCT found inositol 12 g/day produced significantly greater improvement on the Hamilton Depression Rating Scale than placebo by week 4, with no changes in blood, kidney or liver measures ^{10Reference 10Levine et al. · 1995RCTDouble-blind, controlled trial of inositol treatment of depression — randomized controlled trialView study →}; the authors explicitly flagged that replication was crucial. A small 2014 meta-analysis suggested possible benefit, “especially” in premenstrual dysphoric disorder, while cautioning that few studies were available ^{11Reference 11Mukai et al. · 2014Meta-analysisA meta-analysis of inositol for depression and anxiety disorders — meta-analysisView study →}.

Gap: the anchor trial was never convincingly replicated in three decades; the effect rests on one small crossover study, so confidence is low despite the clean tolerability.

A single small double-blind crossover RCT found inositol 18 g/day lowered Yale-Brown Obsessive-Compulsive Scale scores versus placebo ^{9Reference 9Fux et al. · 1996RCTInositol treatment of obsessive-compulsive disorder — randomized controlled trialView study →}. A later open-label trial adding inositol to SSRIs in treatment-refractory OCD was not persuasive.

Gap: one positive small crossover trial and an unconvincing augmentation study; nowhere near the evidence base for established OCD pharmacotherapy.

Inositol has been tried as an add-on for the depressive phase of bipolar disorder. A pilot RCT suggested a larger controlled study was warranted ^{13Reference 13Chengappa et al. · 2000RCTInositol as an add-on treatment for bipolar depression — randomized pilot trialView study →}, and in the STEP-BD equipoize randomized trial inositol was one of three add-on options for treatment-resistant bipolar depression without emerging as clearly effective ^{14Reference 14Nierenberg et al. · 2006RCTTreatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial — randomized controlled trialView study →}. The 2022 nutraceutical clinician guidelines gave inositol only weak/provisional endorsement in psychiatry overall ^{15Reference 15Sarris et al. · 2022ReviewClinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals — review/guidelineView study →}.

Gap: underpowered and inconclusive; used adjunctively at best, and mania-switch risk in bipolar illness means it should not be self-directed.